Thomson Medical Group (SGX:A50) Could Be 48% Below Fair Value After Full Year Results

Why Thomson Medical Group Stock Is Back In Focus After Full Year Results

Thomson Medical Group (SGX:A50) has drawn fresh attention after releasing full year results to June 30, 2026, with sales of S$420.08 million and a narrowed net loss of S$29.7 million.

At a share price of S$0.054, Thomson Medical Group has seen a 1.89% 1 day, 7 day and 30 day share price return following the full year earnings announcement, although the share price return is down 11.48% year to date and the 1 year total shareholder return has declined 15.62%. This suggests recent momentum has firmed slightly against a weaker longer term picture as investors reassess the reduced losses and higher sales.

Compare Thomson Medical Group's shift toward smaller losses with other healthcare operators that combine scale with balance sheet strength by screening for list of solid balance sheet and fundamentals (424 results).

Thomson Medical Group now combines a broad regional hospital and clinic network with slimmer losses, yet the share price has barely lifted in the short term after a weaker multi year run. Is that caution justified at today’s valuation?

Preferred Price-To-Sales Multiple Of 3x For Thomson Medical Group: Is It Justified?

On valuation, Thomson Medical Group trades on a P/S of 3x while the last close sits at S$0.054. That is above both the Singapore healthcare industry average P/S of 2.3x and the peer average of 2.4x, even though the stock is also described as trading 47.8% below an estimated fair value based on future cash flows.

The P/S ratio compares the company’s market value with its revenue. For a healthcare operator like Thomson Medical Group that is still loss making, investors often look at P/S rather than P/E to gauge how much they are paying for each dollar of sales. A higher P/S can imply the market is willing to pay up for the quality or perceived durability of those revenues, despite the absence of profits.

Here, the P/S of 3x is above the estimated fair P/S ratio of 2.8x that our fair ratio model points to. It is also above both the Singapore healthcare industry average of 2.3x and the peer average of 2.4x. That indicates the market is valuing Thomson Medical Group’s revenue stream more richly than sector and peer benchmarks, even though analyst forecasts point to relatively modest revenue growth of 0.01% per year and a low forecast return on equity of 2.1% in three years.

To see how this premium compares with the level our fair ratio model points toward, and what would need to change for the gap to close, check the Explore the SWS fair ratio for Thomson Medical Group.

Result: Price-to-sales of 3x (OVERVALUED)

However, investors in Thomson Medical Group still face risks from ongoing losses and a long stretch of weak multi‑year returns that could keep sentiment cautious.

Find out about the key risks to this Thomson Medical Group narrative.

Another View On Thomson Medical Group’s Valuation

While the current P/S of 3x makes Thomson Medical Group look expensive against industry and peer benchmarks, the SWS DCF model points in the opposite direction. On that view, the stock trades at about a 47.8% discount to an estimated fair value of S$0.10 per share. Which signal should matter more to you right now?

Our DCF model relies on assumptions about future cash flows and discount rates that can shift as new information emerges, so it is only one piece of the picture rather than a verdict on Thomson Medical Group's true worth. Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Thomson Medical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 274 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Thomson Medical Group showing a mix of reduced losses, a higher P/S multiple and a wide DCF discount, the picture is far from one sided. Look through the full set of risks and rewards before making a call by checking the 2 key rewards and 1 important warning sign.

Looking For More Ideas Beyond Thomson Medical Group?

If Thomson Medical Group has you thinking about where to allocate your next dollar, do not stop at a single healthcare stock when there are broader opportunities on offer.

• Target potential mispricing by scanning for companies with strong fundamentals that trade below their estimated worth using the 274 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses with higher yields that focus on consistent shareholder payouts through the 411 dividend fortresses.
• Reduce portfolio stress by filtering for companies that pair healthier balance sheets with resilient financial profiles through the 295 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com